3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
33
Ovarian Neoplasms
9
Breast Neoplasms
9
Pancreatic Neoplasms
8
Metastatic Castration-resistant Prostate Cancer
5
Carcinoma, Renal Cell
5
Urinary Bladder Neoplasms
4
Neoplasm Metastasis
4
Triple Negative Breast Neoplasms
3
Sarcoma
3
Lymphoma, Non-Hodgkin
3
Endometrial Neoplasms
3
Carcinoma, Transitional Cell
3
Wilms Tumor
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Prostatic Neoplasms, Castration-Resistant
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Medulloblastoma
2
Lung Neoplasms
2
Histiocytosis, Langerhans-Cell
2
Hereditary Sensory and Autonomic Neuropathies
2
Hepatoblastoma
2
Glioma
2
Ependymoma
2
Central Nervous System Neoplasms
2
Castration-Resistant Prostate Carcinoma
2
Xanthogranuloma, Juvenile
1
Interventions
enzalutamide
7
Prednisone
7
cabazitaxel
6
Radiosurgery
6
Docetaxel
5
Androgen Antagonists
4
Abiraterone Acetate
4
XRP6258
2
Standard of Care
2
talazoparib
1
sipuleucel-T
1
rucaparib
1
pembrolizumab
1
olaparib
1
gallium 68 PSMA-11
1
fludrocortisone acetate
1
darolutamide
1
apalutamide
1
Zuclomiphene
1
Radiotherapy, Image-Guided
1
Radiotherapy
1
Prednisolone
1
Positron Emission Tomography Computed Tomography
1
Pluvicto
1
Midazolam
1
Lutetium-177
1
Lutetium
1
Lenograstim
1
LY3023414
1
Injections
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostate Cancer Metastatic
×
olaparib
×
Genitourinary
×
Clear all
NCT03434158
2022-11-03
IMANOL
Spanish Oncology Genito-Urinary Group
Phase 2
Completed
16 enrolled